Khandoker Usran Ferdous

Researcher

UAMS

Last publication 2026 Last refreshed 2026-05-16

faculty

4 h-index 20 pubs 66 cited

Research Areas

Links

Lab Website

OverviewAI-generated summary

Khandoker Usran Ferdous investigates the use of oncolytic viruses and immunotherapy as cancer treatments. His work focuses on enhancing immune responses in various cancer models, including hepatocellular carcinoma and pancreatic ductal adenocarcinoma. Ferdous has explored the repurposing of existing vaccines, such as the MMR vaccine, for cancer immunotherapy. His research also examines the development of novel engineered oncolytic viruses designed to overcome cancer's defenses.

His publications detail strategies for improving the efficacy of virotherapy by targeting the tumor microenvironment and combining oncolytic viruses with immune checkpoint blockade. Ferdous has also investigated resistance mechanisms to these therapies and the systemic delivery of synthetic viruses to modulate the tumor microenvironment. His scholarship metrics include an h-index of 4 with 19 publications and 57 citations.

Metrics

h-index: 4
Publications: 20
Citations: 66

Selected Publications

Multimodal reprogramming of the tumor microenvironment by MMR and dual checkpoint blockade in hepatocellular carcinoma models (2025)

DOI OpenAlex
Abstract B022: Reprogramming Apoptotic Resistance in PDAC Through Synthetic Oncolytic Immunotherapy (2025)

DOI OpenAlex
Viral warfare: unleashing engineered oncolytic viruses to outsmart cancer’s defenses (2025)

4 citations DOI OpenAlex
Repeat Systemic Delivery of Cross-Neutralization Resistant Synthetic Vesiculoviruses Immunomodulates the Tumor Microenvironment (2025)

1 citation DOI OpenAlex
Abstract 950: Engineered oncolytic vesiculovirus downsizes pancreatic tumor and boosts immune response (2025)

DOI OpenAlex
Abstract 2155: Phage display discovery of Trop-2 peptide for targeted liposomal chemo-immunotherapy in lung cancer (2025)

DOI OpenAlex
Abstract 945: Live attenuated MMR vaccines modulate tumor immune cell infiltration and synergize with standard of care to prolong survival in preclinical HCC models (2025)

DOI OpenAlex
Abstract 947: Engineering a synthetic oncolytic virus to overcome apoptotic resistance and induce immunogenic cell death in pancreatic ductal adenocarcinoma (2025)

DOI OpenAlex
Resistance signatures to oncolytic vesiculoviruses in pancreatic ductal adenocarcinoma (2025)

3 citations DOI OpenAlex
Enhancing immune response and survival in hepatocellular carcinoma with novel oncolytic Jurona virus and immune checkpoint blockade (2024)

4 citations DOI OpenAlex
Enhancing Neoadjuvant Virotherapy’s Effectiveness by Targeting Stroma to Improve Resectability in Pancreatic Cancer (2024)

4 citations DOI OpenAlex
Abstract 588: Preclinical evaluation of novel chimeric vesiculovirus mediated expression of proteolytic enzymes targeting two major stromal components of pancreatic ductal adenocarcinoma (2024)

DOI OpenAlex
Abstract 5004: Oncolytic Jurona-driven systemic and intratumoral immunotherapy combined with immune checkpoint blockade boost immune response and survival in hepatocellular carcinoma models (2024)

DOI OpenAlex
Repurposing live attenuated trivalent MMR vaccine as cost-effective cancer immunotherapy (2022)

6 citations DOI OpenAlex